Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from AstraZeneca ( (AZN) ) is now available.
On January 20, 2025, AstraZeneca and Daiichi Sankyo announced the U.S. FDA approval of Datroway (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate, for the treatment of HR-positive, HER2-negative metastatic breast cancer in patients who have previously undergone endocrine and chemotherapy. This approval, based on the TROPION-Breast01 Phase III trial results, marks a significant milestone as it provides a new treatment alternative with a 37% reduction in disease progression compared to chemotherapy. The approval enhances AstraZeneca’s oncology portfolio and represents the eighth new medicine out of the 20 the company aims to deliver by 2030, further solidifying its commitment to advancing cancer treatment.
More about AstraZeneca
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, cardiovascular, renal, and metabolism, and respiratory fields. The company has a strong emphasis on oncology, with a robust pipeline of cancer treatments.
YTD Price Performance: 1.09%
Average Trading Volume: 6,101,646
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $205.5B
Learn more about AZN stock on TipRanks’ Stock Analysis page.
